Home > Healthcare > Medical Services > Inpatient and Outpatient Services > Bile Duct Cancer Market

Bile Duct Cancer Market Trends

Report ID: GMI8578
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Bile Duct Cancer Market Trends

The rising incidence of bile duct cancer is a significant driver of the bile duct cancer industry globally.
For instance, as per the National Cancer Institute, the rate of new cases of liver and intrahepatic bile duct cancer in the U.S. is 9.3 per 100,000 men and women per year, with an estimated 41,210 new cases in 2023.
This increase in incidence is attributed to various factors, including aging populations, changing lifestyles, environmental factors, and a rise in risk factors such as chronic liver diseases, bile duct stones, and infections with liver flukes.
Thus, as the incidence of bile duct cancer continues to rise, there is a growing need for effective therapeutic options, driving the growth of the market.
Additionally, development of innovative liver cancer diagnostics is aiding in early detection, further enhances the market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of bile duct cancer reached USD 3.6 billion in 2023 and is set to cross USD 7.4 billion by 2032, owing to the increasing incidence of bile duct cancer globally, the greater demand for effective treatment options, and advancements in medical technology.

The surgery segment held a dominant market share of 36.3% in 2023, owing to the advent of advanced surgical techniques such as minimally invasive approaches that enable more precise and effective procedures.

North America held a market share of 37.8% in 2023 and is expected to reach USD 2.7 billion by 2032, favored by a well-established healthcare infrastructure, high adoption of advanced medical technologies, and increased awareness about early diagnosis & treatment options.

AbbVie Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Fresenius SE & Co. KGaA, Genentech, Inc., GlaxoSmithKline plc, Incyte Corporation, Merck & Co., Inc., Pfizer Inc., and QED Therapeutics.